Biocept Inc

Biocept Inc. is a publicly traded company (Nasdaq: BIOC) headquartered in San Diego, California. The company employs 66 people and generated $63.4 million in revenue. Biocept Inc. specializes in developing and performing clinical laboratory tests for cancer patients with metastatic disease affecting the central nervous system (CNS). Their primary offering, CNSide™, is a specialized assay designed to detect and analyze tumor cells and cell-free DNA from cerebrospinal fluid (CSF). This quantitative testing helps oncologists assess a patient's response to cancer treatment, identify genetic changes linked to therapy resistance, and pinpoint new treatment options for CNS metastasis. Biocept's CLIA-certified and CAP-accredited laboratory plays a crucial role in addressing the complexities of CNS metastasis. Through their testing, oncologists can gain valuable insights into three key aspects: the presence of tumor cells in the CSF, the availability of treatment targets, and the effectiveness of treatment. For more information about Biocept Inc. and their services, visit their website at biocept.com.